Genetic Technologies Limited (GTG) is engaged the provision of genetic testing services. The Company also conducts out-licensing program in respect of its non-coding deoxyribonucleic acid technology and supports a late-stage research project. The Company operates in three segments: Operations, Licensing and Research. The principal geographic segments of the Company include Australia, with the Company�s headquarters being located in Melbourne in the State of Victoria. The Operations segment includes the provision of a range of genetic testing services. The Licensing segment includes the out-licensing of the Group�s non-coding technology. The Research segment includes the undertaking of a range of research and development projects in the field of genetics and related areas. During the fiscal year ended June 30, 2012, the Company launched its new, predictive risk test, BREVAGen. BREVAGen is the clinically validated breast cancer predictive risk assessment tool.